Biotechnology

Lexaria Grants License to Valcon Medical for the European Market

June 2, 2022 9:05 AM

Contract Manufacturing Organization first in Europe to License DehydraTECH Lexaria will receive milestone fees and royalty payments from product sales KELOWNA, BC / ACCESSWIRE / June 2, 2022 / Lexaria Bioscience Corp. (Nasdaq:LEXX) (Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms is pleased to announce the awarding of a European and United Kingdom ("UK") DehydraTECH license for medical cannabis...

Read more

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

June 2, 2022 8:35 AM

Live Video Webcast With Moderated Roundtable With Members of the Xenetic Leadership Team and Surgical Oncology Key Opinion Leader, Allan Tsung, MD on Thursday, June 9th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / June 2, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced...

Read more

Pieris Pharmaceuticals To Present at Jefferies Healthcare Conference

June 2, 2022 8:00 AM

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that management is scheduled to present at the Jefferies Healthcare Conference on Wednesday, June 8, 2022 at 8:00 AM EDT. A webcast of the company's presentation will...

Read more

Manhattan BioSolutions Enters into a Research Collaboration And License Option Agreement with Binghamton University for the New Linker-Payload Technology

June 1, 2022 10:20 AM

NEW YORK, NY / ACCESSWIRE / June 1, 2022 / Manhattan BioSolutions, Inc., an emerging biotechnology company developing new classes of therapeutic biologics for the treatment of advanced and metastatic cancers, today announced a multitarget research and development collaboration and license option agreement with Binghamton University. The collaboration will utilize novel immune-stimulatory linker-payload technology invented at Binghamton...

Read more

Lexaria Announces 2022 Annual Meeting Results

June 1, 2022 9:00 AM

KELOWNA, BC / ACCESSWIRE / June 1, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces the results of the 2022 Annual Meeting (the "Meeting"). On May 31, 2022 at 1:00 p.m. (Pacific Time), the Company held the Meeting whereby there were 2,927,321 shares of the Company represented in person or by proxy at the meeting, constituting 49.2% of the Company's...

Read more

Champions Oncology Announces a Partnership with Cyclica to Develop Small Molecule Therapeutics

May 31, 2022 8:30 AM

HACKENSACK, NJ and TORONTO, ON / ACCESSWIRE / May 31, 2022 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, and Cyclica Inc. ("Cyclica"), a neo-biotech with the vision to advance the most robust and sustainable drug discovery pipeline, announced today a therapeutic development partnership. The partnership...

Read more

Digestive Disease Week 2022 Adds to the Growing Wave of Clinical Evidence Supporting Significant Opportunity for Apollo Endosurgery Products

May 31, 2022 8:30 AM

AUSTIN, TX / ACCESSWIRE / May 31, 2022 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, announced highlights today from data presented at Digestive Disease Week May 21-24. "With more than 120 lectures, presentations, and posters featuring Apollo products, DDW 2022 exemplified Apollo's commitment to building a robust body of clinical evidence...

Read more

Hemogenyx Pharmaceuticals PLC Announces Director/PDMR Shareholding

May 30, 2022 2:00 AM

LONDON, UK / ACCESSWIRE / May 30, 2022 / Hemogenyx Pharmaceuticals plc (LSE:HEMO) announces that it has been notified that Andrew Wright, the Company's Financial Controller and Company Secretary (PDMR), has purchased 1,284,889 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 1.44p per share. Following this transaction, Mr Wright has a total beneficial interest in 4,000,000 Ordinary Shares, representing approximately...

Read more

ONT releases Remora: Most Comprehensive Methylation

May 26, 2022 2:00 AM

Oxford Nanopore integrates "Remora": a tool to enable real-time, high-accuracy epigenetic insights with nanopore sequencing software MinKNOW Oxford Nanopore has today released Remora, a high-performance tool for methylation analysis, into its operating software, MinKNOW, broadening access to direct, PCR-free nanopore sequencing that captures methylation across the whole genome OXFORD, UK / ACCESSWIRE / May 26, 2022 / From today, Oxford Nanopore...

Read more

Cube Psytech Launches Cube Labs Supplement Brand

May 25, 2022 3:01 AM

VANCOUVER, BC / ACCESSWIRE / May 25, 2022 / Cube Psytech Inc. (the "Company" or " CUBE"), a biopharmaceutical and biotechnology company focused on the research and development of functional and psychedelic mushroom technologies for use in natural healthcare products, is excited to share the details of the launch of the Cube Labs brand. Cube Labs is a line of functional supplements that harness the power of adaptogens, including non-psychoactive...

Read more

Edesa Biotech Adds Mechanically Ventilated Patients to Phase 3 ARDS Study

May 24, 2022 7:55 AM

TORONTO, ON / ACCESSWIRE / May 24, 2022 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company has initiated enrollment for a second cohort of patients for the Phase 3 part of a Phase 2/3 study of the company's critical care drug candidate, designated EB05. Edesa is currently evaluating EB05, a monoclonal antibody, in critically ill...

Read more

Thermic Science Backs New TV Show Highlighting HARVARD Award Winning, CANCER KILLING SUCCESS, The Road to 1 MILLION STRONG KILLING CANCERS, Celebrities Dedicated to Raise $20 Million, $20.00 at a Time WORLDWIDE to KEEP KILLING CANCERS for the People

May 24, 2022 7:00 AM

NASHVILLE, TN / ACCESSWIRE / May 24, 2022 / Thermic Science International Corporation, (OTC PINK:ENDO), a U.S. an Advanced Technology Global Consortium, focused on providing key real-time, public access Digital HUB with advanced SaaS solutions. Focused on a hybrid mix of traditional real-world transactions online with real-time inter-connectivity tools for business and personal information and transactions. Thermic Science is pleased to report:...

Read more

Midatech Pharma PLC Announces Posting of Annual Report & Notice of AGM

May 24, 2022 6:40 AM

ABINGDON, OXFORDSHIRE / ACCESSWIRE / May 24, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines, announces that its Notice of Annual General Meeting ("AGM") was posted to shareholders yesterday, along with the Annual Report for the year ended 31 December 2021. The documents are also available in the "Investors" section of the Company's...

Read more

CB Scientific, Inc. Enters Regulatory Testing Phase for Updated myCam Cardiac Event Monitoring Device

May 24, 2022 6:00 AM

Enhanced product to include significant operating enhancements and material design advances over the current offering ESCONDIDO, CA / ACCESSWIRE / May 24, 2022 / CB Scientific. Inc. (OTCQB:CBSC) ("CBSC" or the "Company"), a designer, manufacturer, and distributor of non-invasive ambulatory cardiac monitoring products and services, today announced that it has entered the regulatory testing phase for its updated myCam cardiac event monitoring...

Read more

Ensysce Biosciences Announces Initiation of First Human Abuse Potential Study

May 23, 2022 4:10 PM

~ Nasal Opioid Abuse Being Explored for PF614 ~ ~ Data From Trial Expected in September 2022 ~ SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety and performance focused on reducing abuse and overdose, today announced the initiation of PF614-103, ‘A Randomized,...

Read more

Plandai Biotechnology In Non-Binding Letter of Intent to Acquire Rights to Puriblood’s Leukocyte Reduction Blood Filtration System with Plans to Address the International Blood Filtration Market

May 23, 2022 12:00 AM

SAN DIEGO, CA / ACCESSWIRE / May 23, 2022 / Plandai Biotechnology Inc. (OTC PINK:PLPL) (the "Company") today announced its entry into a non-binding letter of intent to enter into a new business through a proposed product and technology rights licensing agreement with the holder of rights to the unique Puriblood Leukocyte Reduction Blood Filtration System. Puriblood Medical Co., Ltd. [Taipei Exchange], develops and sells blood cell separation...

Read more

Oxford Nanopore Announces Tech Updates

May 20, 2022 2:00 AM

Oxford Nanopore delivers technology update at annual London Calling conference: bringing together years of innovation to showcase one sensing platform for all biological analyses OXFORD, UK / ACCESSWIRE / May 20, 2022 / At the annual London Calling conference, CTO Clive Brown and colleagues James Clarke, Stuart Reid, Lakmal Jayasinghe and Rosemary Sinclair Dokos have provided an Oxford Nanopore tech update summarising the status of its nanopore...

Read more

Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

May 19, 2022 4:30 PM

TORONTO, ON / ACCESSWIRE / May 19, 2022 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that Par Nijhawan, MD, Chief Executive Officer, will present virtually at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022. An on-demand corporate presentation will be accessible to conference attendees starting on Monday, May 24,...

Read more

ONT Opens User Conference, Rich Science Programme

May 19, 2022 5:00 AM

Oxford Nanopore's London Calling conference opens; amongst a breadth of ground-breaking research, increasing attention on human and cancer genomics Conference presentations set to highlight the utility of comprehensive genomic analysis using nanopore sequencing for novel discoveries in human genetics, cancer research, conservation, pathogen genomics and more OXFORD, UK / ACCESSWIRE / May 19, 2022 / The annual London Calling genomics conference,...

Read more

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

May 18, 2022 8:15 AM

Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies for the treatment of hard to treat cancers, today announced that Jeffrey F. Eisenberg, Chief Executive Officer of Xenetic, will present at the H.C. Wainwright Global Investment...

Read more